Physician profile
Robert Saffrin
NPI 1366435034
$2,212.37
in general payments reported to CMS, 2019-2025
29 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $134 · 2021: $211 · 2022: $391 · 2023: $256 · 2024: $503 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.47 | 2020-2025 | Botox, Lupron Depot |
| Rochester Medical Corporation | $158.19 | 2021-2022 | |
| Olympus America INC. | $156.50 | 2020-2024 | Itind System, Soltive, Olympus |
| Pfizer INC. | $135.82 | 2019 | |
| Astellas Pharma US INC | $109.59 | 2019-2024 | Xtandi |
| Janssen Biotech, INC. | $102.93 | 2019 | |
| Boston Scientific Corporation | $101.13 | 2019-2024 | Rezum Generator |
| Coloplast Corp | $63.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $58.82 | 2025 | |
| Neotract INC. | $53.70 | 2019-2020 | |
| Antares Pharma, INC. | $44.84 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Dentsply Ih INC. | $41.43 | 2023 | Lofric |
| Laborie Medical Technologies Corp. | $40.47 | 2024 | |
| Procept Biorobotics Corporation | $33.27 | 2022 | |
| Immunitybio, INC. | $29.11 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $26.14 | 2019 | |
| Avation Medical, INC. | $23.43 | 2025 | Vivally System |
| Smith+Nephew, INC. | $22.54 | 2025 | Stravix Pl |
| Allergan, INC. | $19.32 | 2020 | |
| Verity Pharmaceuticals INC. | $18.99 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $18.68 | 2019 | |
| Ethicon US, LLC | $17.87 | 2021 | |
| Endo Pharmaceuticals INC. | $17.44 | 2019 | |
| Janssen Scientific Affairs, LLC | $16.81 | 2019 | |
| Accord Healthcare, INC. | $15.53 | 2022 | |
| Teleflex LLC | $14.30 | 2022 | |
| Urovant Sciences INC | $12.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.72 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$122,060.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Saffrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.